reference/36147715

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/36147715

Outgoing Links

Predicate	Object
contentType	Randomized Controlled Trial\|Clinical Trial, Phase II\|Journal Article
endingPage	199
issn	0085-2538
issueIdentifier	1
pageRange	189-199
publicationName	Kidney International
startingPage	189
bibliographicCitation	Zhang H, Rizk DV, Perkovic V, Maes B, Kashihara N, Rovin B, Trimarchi H, Sprangers B, Meier M, Kollins D, Papachristofi O, Milojevic J, Junge G, Nidamarthy PK, Charney A, Barratt J. Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy. Kidney Int. 2024 Jan;105(1):189–99. doi: 10.1016/j.kint.2023.09.027. PMID: 37914086.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0001-5639-0210 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1ea5c7ddde6e611a7ab7adc69b6ea3ba http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2f7bddcb5b2a4ac4d1b5452f20ab9e18 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-6921-4811 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d5ab2db8be88056267a67863e9edd0ce http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_416e3b704d7e90fc8ed8eca296515799 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_10d0cfa115951205ea138dbcfebb9560 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_638244a44427a7960a526b8d322341fe http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a25df2ec6ac92923c2cdc685aefe7c68 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2a5d7e23946ca6e92d3a27f9b42dcf3a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_041603452a1f1cd158048208f89f9f12 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_dbfe257a994ee0114c43b35582f42ac1 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_674dc8bd1f661622c552cd17840d355c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d44c1385f2aeb87a8164e3dc06a10a56 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4836ca07742be23683a080773fdaf992 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_efc1cb4726169a9fdb97ae1f1e9e1fce
date	202401
identifier	https://pubmed.ncbi.nlm.nih.gov/37914086 https://doi.org/10.1016/j.kint.2023.09.027
isPartOf	https://portal.issn.org/resource/ISSN/0085-2538 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/5428
language	English
source	https://www.crossref.org/ https://pubmed.ncbi.nlm.nih.gov/
title	Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy
discusses	http://id.nlm.nih.gov/mesh/M0011157 http://id.nlm.nih.gov/mesh/M0023752
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D005922Q000473
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D004311 http://id.nlm.nih.gov/mesh/D015415 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D007155Q000627 http://id.nlm.nih.gov/mesh/D003170 http://id.nlm.nih.gov/mesh/D016896

Showing number of triples: 1 to 42 of 42.